| |
Rescue studies are not meant to be taken lightly – logistical hurdles and communication challenges are aplenty. Despite this, Premier Research doesn’t back down. See how our unique advantages helped a sponsor recover a Phase 1 oncology trial: Learn More
Premier Research. Built for Biotech℠
|
|
Today’s Big NewsOct 9, 2023 |
|
Thursday, October 12, 2023 | 11am ET / 8am PT A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks? In this webinar, leaders in industry and academia discuss their experiences using innovative tools to study and develop therapeutics against influenza, SARS-CoV-2, dengue viruses, and more. Register now.
|
|
| By Annalee Armstrong,Max Bayer Eikon Therapeutics, a biotech that snatched several big-name executives from Merck & Co. and raked in some of the largest financing rounds in recent memory, has cut staff in an effort to “become more efficient.” |
|
|
|
By Gabrielle Masson You're not going to hear a private biotech trumpeting a down round as they announce a new batch of funding, but industry experts say the broader market trend has seeped into the sector. That's because a down round used to ring red-hot alarm bells. But as valuations change, investors say the meaning of a down round might too. |
By Nick Paul Taylor AnaptysBio has set the stage for negotiations over its rare skin disease drug candidate, delivering phase 3 data that suggest the asset can challenge Boehringer Ingelheim in generalized pustular psoriasis (GPP). |
Sponsored by Trinity Life Sciences In a dynamic landscape, three emerging trends have the power to reshape the complexities of pharmaceutical commercialization. |
By James Waldron While the final frontier of Alzheimer’s work is patrolled by U.S. Big Pharmas like Eli Lilly and Biogen, the U.K. is sending out its own mission in the form of AstronauTx. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By Helen Floersh The lab of Nobel laureate Jennifer Doudna showed that CRISPR can lead to a phenomenon known as chromosome loss in T cells, but that preventing it lies in the order of gene editing operations. |
By Angus Liu After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the KRAS drugmaker. |
By Nick Paul Taylor QHP Capital has slotted another company into its portfolio of contract service providers, snapping up cell and gene therapy specialist Applied StemCell and outlining plans to support its expansion. |
By Andrea Park Revenues across the medtech industry clocked in at $573 billion for all of 2022, marking annual growth of just 3.5%—the industry’s lowest rate since 2015. |
By Angus Liu Despite an endorsement from an advisory committee, the FDA has come to a different conclusion on the benefit-risk profile for Alnylam’s Onpattro in the rare heart disease transthyretin amyloidosis cardiomyopathy (ATTR-CM). |
By Heather Landi,Paige Minemyer The latest news and updates from the HLTH 2023 conference: Uber and Optum team up to simplify access to Medicare Advantage supplemental benefits. |
By Kevin Dunleavy People who use Novo Nordisk’s popular weight-loss drugs are taking on a small risk of developing severe stomach problems, according to research conducted by the University of British Columbia. The investigation indicates a link between Novo’s GLP-1 products and gastroparesis, pancreatitis and bowel obstruction. Still, the investigators emphasized that the risk was very small. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| |
|
